Quick Answer
| What actually changed | What did not change |
|---|---|
| An FDA advisory committee voted to recommend BPC-157, TB-500, and MOTS-c for the 503A Bulks List | None of them are on the 503A Bulks List yet |
| The recommendation is public and on the record | None of them is an FDA-approved drug |
| Regulatory attention on these compounds has clearly increased | Compounding them still isn't legal under Section 503A |
The July 2026 PCAC Vote
The FDA's Pharmacy Compounding Advisory Committee (PCAC) met over two days, July 23 and 24, 2026, to review bulk drug substances nominated for inclusion on the Section 503A Bulk Drug Substances List. That list matters because a substance has to be on it, have its own U.S. Pharmacopoeia monograph, or be a component of an FDA-approved drug, before a compounding pharmacy can legally prepare it under Section 503A of the Federal Food, Drug, and Cosmetic Act.
Seven peptides were on the agenda. BPC-157, KPV, TB-500, and MOTS-c were reviewed on the first day. Emideltide, the substance name used in this process for DSIP, along with Semax and Epitalon, were reviewed on the second day.
What Was Recommended
The committee voted to recommend six of the seven peptides for the 503A Bulks List: BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon. Emideltide (DSIP) was the one substance the committee did not recommend. The margins on most of these votes were narrow, reported as roughly 8 to 6 with an abstention on some of the day-one compounds, which reflects a genuinely split committee rather than a clear consensus.
Worth knowing: multiple outlets covering the vote also reported that a majority of the committee members who voted in favor had industry ties to the peptide or compounding space, and that FDA's own staff scientists had reportedly recommended against inclusion before the vote. Neither of those facts changes what the vote legally means, but they're part of the full picture of how contested this recommendation was.
What This Vote Does NOT Mean
This is the part that gets lost in headlines. A PCAC recommendation is nonbinding. The FDA is not required to follow it, and as of this writing, the FDA has not adopted it. For any of these peptides to actually become legal to compound under Section 503A, one of two things would need to happen: the FDA would need to complete a formal notice-and-comment rulemaking process, which includes publishing a proposed rule, taking public comments, and then issuing a final rule, or Congress would need to amend the underlying statute directly. Neither path is quick, and neither is guaranteed to result in the same outcome as the committee's recommendation.
It's also worth separating two different kinds of legal status that are easy to conflate. Being added to the 503A Bulks List would make it legal for a licensed compounding pharmacy to prepare a substance under specific conditions. That is not the same thing as FDA drug approval, which requires the substance to go through the full clinical trial process the FDA uses to evaluate a new drug's safety and effectiveness. Even in the best case for compounding advocates, none of these peptides would suddenly become an FDA-approved medication as a result of this process.
Why the Vote Matters Anyway
Even as a nonbinding recommendation, this vote is a meaningful signal. It's the first time this specific group of research peptides has gone through a formal FDA advisory review process at all, and it puts the question of their regulatory future on the public record in a way it wasn't before. Whichever direction the FDA ultimately goes, this meeting is likely to be referenced as the starting point of that decision, which is part of why it's worth understanding clearly rather than assuming either "now it's legal" or "nothing happened."
What Happens Next
The realistic next steps are on the FDA's timeline, not a fixed date. The agency could open a formal rulemaking process, which would include a public comment period before any final rule takes effect. It could also decline to act on the recommendation, or take a partial approach, and it retains its normal enforcement authority against compounding pharmacies in the meantime regardless of what the committee recommended. Anyone tracking this closely should watch for a Federal Register notice, which is where a formal proposed rule would actually appear.
For the current regulatory status of each individual peptide, including compounds not part of this specific July 2026 vote, see the FDA Peptide Status Tracker.
Related Reading
For background on how the 503A framework works in general, see What Is FDA's 503A Bulks List?. For what a compounded peptide actually is and how it differs from a manufactured research chemical, see What Is a Compounded Peptide?. For the underlying human evidence picture on these specific compounds, independent of their regulatory status, see BPC-157 Human Studies, TB-500 Human Studies, and MOTS-c Human Studies.